A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.

Autor:	Yang, Ji-Xin, Yang, Yu-Qing, Hu, Wen-Yu, Yang, Lu, Wu, Jiang, Wen, Xin-Xin, Yu, Jing, Huang, Mei-Ling, Xu, Dong-Dong, Tie, Dan-Chen, Wang, Lei, Li, Fan-Fan, Li, Nan-Lin
Předmět:	BREAST tumor prevention THERAPEUTIC use of monoclonal antibodies THERAPEUTIC use of antineoplastic agents CARDIOTOXICITY CONFIDENCE intervals EPIDERMAL growth factor receptors TRASTUZUMAB CYCLOPHOSPHAMIDE DESCRIPTIVE statistics COMBINED modality therapy PACLITAXEL BREAST tumors HEART failure PATIENT safety
Zdroj:	Oncologist; Jan2024, Vol. 29 Issue 1, pe15-e24, 10p
Abstrakt:	Background Neoadjuvant trastuzumab/pertuzumab (HP) plus chemotherapy for HER2-positive breast cancer (BC) achieved promising efficacy. The additional cardiotoxicity still existed. Brecan study evaluated the efficacy and safety of neoadjuvant pegylated liposomal doxorubicin (PLD)/cyclophosphamide and sequential nab -paclitaxel based on HP (PLD/C/HP- nab P/HP). Patients and Methods Brecan was a single-arm phase II study. Eligible patients with stages IIA-IIIC HER2-positive BC received 4 cycles of PLD, cyclophosphamide, and HP, followed by 4 cycles of nab -paclitaxel and HP. Definitive surgery was scheduled after 21 days for patients completing treatment or experiencing intolerable toxicity. The primary endpoint was the pathological complete response (pCR). Results Between January 2020 and December 2021, 96 patients were enrolled. Ninety-five (99.0%) patients received 8 cycles of neoadjuvant therapy and all underwent surgery with 45 (46.9%) breast-conserving surgery and 51 (53.1%) mastectomy. The pCR was 80.2% (95%CI, 71.2%-87.0%). Four (4.2%) experienced left ventricular insufficiency with an absolute decline in LVEF (43%-49%). No congestive heart failure and ≥grade 3 cardiac toxicity occurred. The objective response rate was 85.4% (95%CI, 77.0%-91.1%), including 57 (59.4%) complete responses and 25 (26.0%) partial responses. The disease control rate was 99.0% (95%CI, 94.3%-99.8%). For overall safety, ≥grade 3 AEs occurred in 30 (31.3%) and mainly included neutropenia (30.2%) and asthenia (8.3%). No treatment-related deaths occurred. Notably, age of >30 (P =.01; OR = 5.086; 95%CI, 1.44-17.965) and HER2 IHC 3+ (P =.02; OR = 4.398; 95%CI, 1.286-15.002) were independent predictors for superior pCR (ClinicalTrials.gov Identifier NCT05346107). Conclusion Brecan study demonstrated the encouraging safety and efficacy of neoadjuvant PLD/C/HP- nab P/HP, suggesting a potential therapeutic option in HER2-positive BC. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu